NCT04658329Unknown不适用
Cohorte ANRS CO5 "Cohorte Nationale VIH2"
适应症
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 1,185
- 试验地点
- 29
- 主要终点
- Study HIV-2 infection rate in adult patients followed in France
研究概览
简要总结
The HIV2 study is an open cohort of prospective, multicentric, national observation. The main objective is to study HIV-2 infection in adult patients followed in France.
详细描述
The secondary objectives are :
- Describe the epidemiological and clinical characteristics of participants infected with HIV-2, and the immuno-virological characteristics of the infection.
- To study the clinical and immunological progression of HIV-2 infection and the prognostic factors of this evolution.
- Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
- Allow an evaluation of the care practices of participants followed in French hospitals
- Provide a bank of clinical-biological data and samples allowing the performance of virological and / or immunological studies on HIV-2 infection.
The follow-up of the participants is different according to the therapeutic status of the participants, naive of antiretroviral treatment or already treated with antiretrovirals.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-2 infection only, diagnosed by ELISA, confirmed by Western-Blot test,
- •Follow-up in consultation or hospitalization in one of the investigating centers,
- •Age greater than or equal to 18 years,
- •Prolonged follow-up possible, residence in France planned for at least one year,
- •Consent to participate,
- •Long-term medical care possible for the participant, or by medical aid (AME), or declaration of obtaining AME at the time of inclusion.
排除标准
- •HIV-1 infection
- •Double HIV-1 + HIV-2 seropositivity
结局指标
主要结局
Study HIV-2 infection rate in adult patients followed in France
时间窗: At the baseline
次要结局
- Pourcentage of response to antiretroviral treatment evaluate by serology samples(Up to 25 years)
- Pourcentage of good management practices of patients followed in French hospitals evaluate by results(Up to 25 years)
- The epidemiological parameters and progression of patients infected with HIV-2 evaluate by a questionnaire(Up to 25 years)
- Pourcentage of patient with HIV-2(Up to 25 years)
- The clinical progression of patients infected HIV-2 evaluate by samples: biological examinations(Up to 25 years)
- The rate of immuno-virological charge of the infection evaluate by serology samples(Up to 25 years)
研究者
研究点 (29)
Loading locations...
相似试验
进行中（未招募）
不适用
Estudio fase II prospectivo, abierto, multicéntrico de Gemcitabina, Oxaliplatino y Dexametasona + Rituximab en pacientes con linfomas agresivos (difuso de céluls grandes B y del manto) en recaída o resistencia no subsidiarios de ser sometidos a quimioterapia intensa y trasplante autólogo de progenitores hemocitopoyéticos. - GEL-TAMO/REUCTR2008-007305-36-ESGELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea)
终止
2 期
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05148195Jiangsu Simcere Pharmaceutical Co., Ltd.86
进行中（未招募）
不适用
Estudio en fase II, multicentrico, prospectivo, abierto, de tratamiento anticipado con valganciclovir de la infección por citomegalovirus en el transplante alogénico de progenitores hematopoyético ”.EUCTR2005-002813-19-ESFundación Pethema
进行中（未招募）
不适用
Etude évaluant l'efficacité et la sécurité du SUnitinib chez des patients atteints d’adénocarcinome rénal avancé ou métastatique et administré selon un schéma alteRnatiF.cancer du rein métastatiqueEUCTR2015-002575-16-FRCentre Hospitalier Régional Universitaire de Besançon
进行中（未招募）
不适用
Etude prospective, multicentrique, de phase II testant la faisabilité d’un traitement d’entretien par l’alemtuzumab chez des patients porteurs de leucémie lymphoïde chronique, traités et répondant à l’alemtuzumab - Campath-LLC-entretieChronic lymphoid leukemia in complete remission (CR) or partial remission (PR)EUCTR2008-006491-30-FRCentre Henri Becquerel